TimesSquare Capital Management LLC Cuts Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

TimesSquare Capital Management LLC decreased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 150,219 shares of the company’s stock after selling 8,200 shares during the quarter. IDEXX Laboratories makes up 1.2% of TimesSquare Capital Management LLC’s investment portfolio, making the stock its 23rd biggest holding. TimesSquare Capital Management LLC owned approximately 0.18% of IDEXX Laboratories worth $81,108,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Nordea Investment Management AB increased its holdings in IDEXX Laboratories by 15.5% during the 1st quarter. Nordea Investment Management AB now owns 13,719 shares of the company’s stock worth $7,447,000 after purchasing an additional 1,839 shares during the period. Brevan Howard Capital Management LP acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth about $3,183,000. Assenagon Asset Management S.A. boosted its position in shares of IDEXX Laboratories by 25.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 43,593 shares of the company’s stock worth $24,196,000 after acquiring an additional 8,831 shares in the last quarter. Carderock Capital Management Inc. boosted its position in shares of IDEXX Laboratories by 35.7% during the 4th quarter. Carderock Capital Management Inc. now owns 16,416 shares of the company’s stock worth $9,112,000 after acquiring an additional 4,315 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its position in shares of IDEXX Laboratories by 9.4% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 42,045 shares of the company’s stock worth $23,307,000 after acquiring an additional 3,627 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Bruce L. Claflin sold 200 shares of the stock in a transaction on Friday, May 17th. The stock was sold at an average price of $540.80, for a total transaction of $108,160.00. Following the sale, the director now owns 161 shares in the company, valued at approximately $87,068.80. The sale was disclosed in a legal filing with the SEC, which is available through this link. 2.11% of the stock is owned by insiders.

IDEXX Laboratories Price Performance

NASDAQ IDXX traded up $4.96 during mid-day trading on Friday, hitting $492.74. The stock had a trading volume of 351,816 shares, compared to its average volume of 465,319. IDEXX Laboratories, Inc. has a 52-week low of $372.50 and a 52-week high of $583.39. The company has a market cap of $40.70 billion, a price-to-earnings ratio of 47.70, a P/E/G ratio of 3.98 and a beta of 1.32. The company has a 50 day simple moving average of $500.41 and a 200 day simple moving average of $522.33. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.13. The firm had revenue of $964.10 million during the quarter, compared to the consensus estimate of $965.43 million. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. Equities analysts forecast that IDEXX Laboratories, Inc. will post 11.03 EPS for the current fiscal year.

Analyst Ratings Changes

IDXX has been the subject of several analyst reports. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday. Barclays decreased their target price on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. Morgan Stanley decreased their target price on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research report on Tuesday, May 14th. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. Finally, Stifel Nicolaus decreased their target price on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research report on Monday, June 24th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus price target of $586.63.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.